Clinical Trials

The HDHC considers the participation of its doctors in clinical trials important as these are the most basic element for scientific research and innovative medical treatments. Conducting clinical trials is an important activity of our Clinic as it enables eligible patients to have access to new treatments before they are made available to the wider population and to actively support scientific research. The process of conducting clinical trials at HDHC is carried out in full compliance with the current European and national regulatory framework with the main focus on the safety of the patients participating in them.

 

The success of clinical trials depends on the participation of patients and therefore, if you would like to participate and help promote scientific research, we invite you to contact your treating physician so that he/she can direct you to the specialized researchers for more information.

 

 

 

NON-SMALL CELL LUNG CANCER, STAGE 3

In Stage 3, the lung cancer has not spread outside the chest, but is inoperable. The classic treatment in these cases is the combination of chemotherapy with radiation therapy, followed by maintenance immunotherapy. At the 4th Oncology Clinic of Henry Dunant Hospital Center two clinical studies are available for this stage of disease, which enable the patient to receive a combination of two immunotherapy agents, either during chemoradiotherapy, or during maintenance immunotherapy.

For more information you can contact the Hospital’s 4th Oncology Clinic, tel. 21069723246.

Head: Internist - Oncologist, Ioannis Mountzios, Director of the 4th Oncology Clinic

NON-SMALL CELL LUNG CANCER, STAGE 4 (METASTATIC)

At this stage, the lung cancer has metastasized to distant organs, such as the liver, bones, adrenal glands and brain. At this stage, treatment is always individualized. In the 4th Oncology Clinic of the Hospital, it is possible to carry out extensive genetic testing, based on the results of which the appropriate treatment is determined. In patients with high expression of the immunotherapy marker PD-L1 (>50%), there are clinical studies available with the addition of molecular therapies or specific drugs that are monoclonal antibody-chemotherapy complexes (antibody-drug conjugates). In patients who have mutations in the EGFR gene and worsening of their disease, a dual-targeted molecular clinical study is available. In patients with KRAS gene mutations, clinical studies are available with the newer KRAS inhibitors or in combinations with immunotherapy or antibody-drug conjugates. 

For more information you can contact the Hospital’s 4th Oncology Clinic, tel. 21069723246.

Head: Internist - Oncologist, Ioannis Mountzios, Director of the 4th Oncology Clinic

METASTATIC NON-SMALL CELL LUNG CANCER - RECURRENCE AFTER CHEMOTHERAPY AND IMMUNOTHERAPY

This type of cancer refers to a group of patients with a difficult prognosis and limited treatment options. At the 4th Oncology Clinic, a wide range of treatment options are available depending on the molecular profile of each tumor. There are clinical studies for patients with mutations in specific oncogenes or studies with monoclonal antibody-chemotherapy complex (antibody-drug conjugates) for patients who do not have a specific mutation.

For more information you can contact the Hospital’s 4th Oncology Clinic, tel. 21069723246.

Head: Internist - Oncologist, Ioannis Mountzios, Director of the 4th Oncology Clinic

SMALL CELL LUNG CANCER - LIMITED DISEASE

These are patients with small cell lung cancer, which is confined within the chest and can be irradiated. The classic treatment in these cases is the combination of chemotherapy with radiation therapy, called chemoradiotherapy. In the Hospital’s 4th Oncology Clinic, a clinical study is available that allows patients to receive immunotherapy in combination with chemoradiotherapy followed by immunotherapy in combination with a molecular inhibitor as maintenance treatment.

For more information you can contact the Hospital’s 4th Oncology Clinic, tel. 21069723246.

Head: Internist - Oncologist, Ioannis Mountzios, Director of the 4th Oncology Clinic

SMALL CELL LUNG CANCER - EXTENSIVE DISEASE

These are patients with small cell lung cancer, which has metastasized to distant organs, such as the liver, bones, adrenal glands or brain. The classic treatment in these cases is the combination of chemotherapy with immunotherapy, called chemo-immunotherapy. In the Hospital’s 4th Oncology Clinic, two clinical studies are available that allow patients to receive either double immunotherapy in order to prevent recurrence, or maintenance treatment with immunotherapy and a biological agent.

For more information you can contact the Hospital’s 4th Oncology Clinic, tel. 21069723246.

Head: Internist - Oncologist, Ioannis Mountzios, Director of the 4th Oncology Clinic

NEW THERAPEUTIC APPROACH FOR PATIENTS WITH MILD MEMORY DISORDERS

The 2nd Neurology Clinic of Henry Dunant Hospital Center is conducting a research study concerning patients with mild memory disorders who either have mild mental impairment (before progressing to dementia) or are in an early stage of Alzheimer's disease. 

This specific study investigates the compound semaglutide in the therapeutic approach of the above patients along with intensive monitoring (neurological examination, complete laboratory testing, neuropsychological tests). 

The study aims to investigate the beneficial effect of the compound semaglutide in these specific patients.

The study has started recruiting patients since November 2021 and is ongoing.

For further information and to book an appointment in order to undergo evaluation for possible inclusion in the study, please call at 2106979038